Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Urruticoechea · SciRah

Researcher profile · Semantic Scholar

A. Urruticoechea

Share profile

A. Urruticoechea — researcher profile on SciRah

h-index: 30
Works: 119
Citations: 3,878

Most-cited papers

Recent advances in cancer therapy: an overview.
A. Urruticoechea, R. Alemany, J. Balart, A. Villanueva +2 more
2010Current pharmaceutical design443 citations
Semantic Scholar
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
M. Palafox, I. Ferrer, Pasquale Pellegrini, S. Vila +10 more
2012Cancer Research193 citations
Semantic Scholar
Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer
C. Maxwell, J. Benítez, L. Gómez-Baldó, A. Osorio +140 more
2011PLoS Biology191 citations Open access
Semantic Scholar
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
C. Saura, J. Bendell, G. Jerusalem, S. Su +13 more
2014Clinical Cancer Research129 citations
Semantic Scholar
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines
T. Puig, H. Aguilar, S. Cufí, G. Oliveras +6 more
2011Breast Cancer Research98 citations Open access
Semantic Scholar
Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment
J. Amézaga, B. Alfaro, Y. Ríos, A. Larraioz +3 more
2018Supportive Care in Cancer96 citations Open access
Semantic Scholar
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy.
A. Urruticoechea, M. Rizwanullah, S. Im, A. Ruíz +7 more
2017Journal of Clinical Oncology95 citations
Semantic Scholar
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment
S. Cufí, A. Vázquez-Martín, C. Oliveras-Ferraros, Bruna Corominas-Faja +3 more
2012OncoTarget76 citations Open access
Semantic Scholar
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population
J. Gómez‐Miragaya, M. Palafox, L. Paré, G. Yoldi +18 more
2017Stem Cell Reports73 citations Open access
Semantic Scholar
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer
H. Aguilar, X. Solé, N. Bonifaci, Jordi Serra-Musach +7 more
2010Oncogene73 citations
Semantic Scholar
Avoiding Axillary Treatment in Sentinel Lymph Node Micrometastases of Breast Cancer: A Prospective Analysis of Axillary or Distant Recurrence
S. Pernas, M. Gil, A. Benítez, M. Bajén +9 more
2010Annals of Surgical Oncology69 citations
Semantic Scholar
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment
A. Araujo, A. Abaurrea, P. Azcoaga, J. I. López-Velazco +26 more
2022Journal of Clinical Investigation63 citations Open access
Semantic Scholar
Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors
N. Travier, A. Fonseca‐Nunes, C. Javierre, E. Guillamó +18 more
2013Medical Oncology61 citations
Semantic Scholar
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study
M. Ruíz-Borrego, B. Jímenez, S. Antolín, J. García-Sáenz +13 more
2018Investigational new drugs55 citations
Semantic Scholar
Altered Red Blood Cell Membrane Fatty Acid Profile in Cancer Patients
J. Amézaga, S. Arranz, A. Urruticoechea, G. Ugartemendia +5 more
2018Nutrients54 citations Open access
Semantic Scholar
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
B. Pistilli, T. Pluard, A. Urruticoechea, D. Farci +11 more
2017Breast Cancer Research and Treatment53 citations Open access
Semantic Scholar
Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non–Small-Cell Lung Cancer
L. Sánchez-Magraner, J. Gumuzio, J. Miles, Nicole Quimi +25 more
2023Journal of Clinical Oncology51 citations Open access
Semantic Scholar
VAV3 mediates resistance to breast cancer endocrine therapy
H. Aguilar, A. Urruticoechea, P. Halonen, K. Kiyotani +41 more
2014Breast Cancer Research44 citations Open access
Semantic Scholar
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
A. Ocaña, M. Gil-Martin, S. Antolín, M. Atienza +14 more
2019Breast Cancer Research and Treatment43 citations
Semantic Scholar
Basal/HER2 breast carcinomas
B. Martín-Castillo, C. Oliveras-Ferraros, A. Vázquez-Martín, S. Cufí +6 more
2013Cell Cycle42 citations Open access
Semantic Scholar
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies
A. Martínez-Aranda, Vanessa Hernández, E. Guney, L. Muixi +15 more
2015OncoTarget35 citations Open access
Semantic Scholar
Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)
M. Quintela-Fandino, A. Urruticoechea, J. Guerra, Miguel Gil +10 more
2014British Journal of Cancer35 citations Open access
Semantic Scholar
Acetyl-CoA carboxylase 1 controls a lipid droplet–peroxisome axis and is a vulnerability of endocrine-resistant ER+ breast cancer
Marina Bacci, Nicla Lorito, Alfredo Smiriglia, Angela Subbiani +20 more
2024Science Translational Medicine33 citations Open access
Semantic Scholar
Novel anti‐fatty acid synthase compounds with anti‐cancer activity in HER2+ breast cancer
G. Oliveras, A. Blancafort, A. Urruticoechea, Ó. Campuzano +5 more
2010Annals of the New York Academy of Sciences31 citations
Semantic Scholar
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis
N. Paracha, A. Reyes, V. Diéras, I. Krop +2 more
2020Breast Cancer Research and Treatment30 citations Open access
Semantic Scholar
Design of a multinational randomized controlled trial to assess the effects of structured and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life: the EFFECT study
A. Hiensch, E. Monninkhof, M. Schmidt, E. Zopf +20 more
2022Trials29 citations Open access
Semantic Scholar
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
A. Llombart-Cussac, J. Pérez-García, M. Ruíz Borrego, P. Tolosa +24 more
2024EClinicalMedicine26 citations Open access
Semantic Scholar
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
A. Ocaña, M. Gil-Martin, Miguel Martín, F. Rojo +10 more
2017OncoTarget25 citations Open access
Semantic Scholar
Biological Convergence of Cancer Signatures
X. Solé, N. Bonifaci, N. López-Bigas, A. Berenguer +10 more
2009PLoS ONE25 citations Open access
Semantic Scholar
The Urinary Transcriptome as a Source of Biomarkers for Prostate Cancer
C. Solé, I. Goicoechea, Alai Goñi, Maike Schramm +16 more
2020Cancers23 citations Open access
Semantic Scholar
Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)
M. Dickler, R. Villanueva, J. A. Perez Fidalgo, I. Mayer +26 more
201818 citations
Semantic Scholar
A randomized controlled trial of the effectiveness of a one-to-one peer support intervention on resilience, social support, and salivary cortisol in recently diagnosed women with breast cancer.
Ibane Aizpurua-Perez, A. Arregi, David Gonzalez, A. Urruticoechea +6 more
2024European Journal of Oncology Nursing17 citations Open access
Semantic Scholar
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
T. Pascual, Miguel Martín, A. Fernández-Martínez, L. Paré +20 more
2019Frontiers in Oncology17 citations Open access
Semantic Scholar
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice
S. Pernas, M. Gil-Gil, M. O. de Olza, A. Gumà +11 more
2012Breast Cancer Research and Treatment17 citations
Semantic Scholar
Trastuzumab plus capecitabine with or without pertuzumab in patients with HER2-positive MBC whose disease has progressed during or following trastuzumab-based therapy for first-line metastatic disease: A multicenter, randomized, two-arm, phase II study (PHEREXA).
M. Muñoz-Mateu, A. Urruticoechea, R. Šeparović, J. Erfán +12 more
2011Journal of Clinical Oncology16 citations
Semantic Scholar
PHEREXA: A phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting.
A. Urruticoechea, M. Rizwanullah, S. Im, A. Sánchez-Ruiz +7 more
201615 citations
Semantic Scholar
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma
Juanita Lopez, J. Lai-Kwon, R. Molife, L. Welsh +16 more
2023British Journal of Cancer14 citations Open access
Semantic Scholar
Evidence for a link between TNFRSF11A and risk of breast cancer
N. Bonifaci, M. Palafox, Pasquale Pellegrini, A. Osorio +33 more
2011Breast Cancer Research and Treatment14 citations
Semantic Scholar
Removal of the internal mammary sentinel node in breast cancer
Anna Domènech-Vilardell, M. Bajén, A. Benítez, Y. Ricart +7 more
2009Nuclear medicine communications13 citations
Semantic Scholar
A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer
J. I. López-Velazco, Sara Manzano, M. Otaño, K. Elorriaga +7 more
2024Breast Cancer Research12 citations Open access
Semantic Scholar
Altered Levels of Desaturation and ω-6 Fatty Acids in Breast Cancer Patients’ Red Blood Cell Membranes
J. Amézaga, G. Ugartemendia, A. Larraioz, N. Bretaña +5 more
2020Metabolites12 citations Open access
Semantic Scholar
Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients: FN14 and GRP94 from Diagnosis to Prophylaxis
A. Martínez-Aranda, Vanessa Hernández, F. Moreno, N. Baixeras +9 more
2017Frontiers in Oncology12 citations Open access
Semantic Scholar
Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.
A. Urruticoechea, M. Rizwanullah, S. Im, A. Ruíz +7 more
201811 citations
Semantic Scholar
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment
A. Araujo, A. Abaurrea, P. Azcoaga, J. I. López-Velazco +26 more
2022Journal of Clinical Investigation9 citations Open access
Semantic Scholar
PD09-03: Phase I/II Study of BKM120 in Combination with Trastuzumab in Patients with HER2 Overexpressing Metastatic Breast Cancer Resistant to Trastuzumab-Containing Therapy.
C. Saura, J. Bendell, G. Jerusalem, B. Graña-Suárez +14 more
20119 citations
Semantic Scholar
Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer
José Ángel Palomeque, Gabriel Serra-Mir, Sandra Blasco-Benito, Helena Brunel +19 more
2025Journal of Clinical Investigation8 citations
Semantic Scholar
Discovery and Proof-of-Concept Study of Nuclease Activity as a Novel Biomarker for Breast Cancer Tumors
Luiza I. Hernandez, M. Araúzo-Bravo, Daniela Gerovska, R. R. Solaun +8 more
2021Cancers8 citations Open access
Semantic Scholar
Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry.
R. Rigo-Bonnin, S. Cobo-Sacristán, Núria Gonzalo-Diego, H. Colom +4 more
2016Journal of Pharmaceutical and Biomedical Analysis8 citations
Semantic Scholar
Omega 6 polyunsaturated fatty acids in red blood cell membrane are associated with xerostomia and taste loss in patients with breast cancer.
J. Amézaga, G. Ugartemendia, A. Larraioz, N. Bretaña +5 more
2021Prostaglandins, Leukotrienes and Essential Fatty Acids7 citations Open access
Semantic Scholar
Abstract CT219: Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX Recurrence Score®(RS) 18-25 or 26-100. Analysis of RS changes at surgery (DxCARTES trial)
A. Cussac, J. Pérez-García, Á. Guerrero, B. Bermejo +18 more
2019Clinical Trials7 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Climent×6
Invite
F. Climent — researcher profile on SciRah
N. Bonifaci×5
Invite
N. Bonifaci — researcher profile on SciRah
H. Aguilar×5
Invite
H. Aguilar — researcher profile on SciRah
G. Ugartemendia×5
Invite
G. Ugartemendia — researcher profile on SciRah

×5

Invite

M. Muñoz — researcher profile on SciRah

J. I. López-Velazco×5

Invite

J. I. López-Velazco — researcher profile on SciRah

Invite

M. Caffarel — researcher profile on SciRah

E. González-Suárez×4

Invite

E. González-Suárez — researcher profile on SciRah

Invite

V. Moreno — researcher profile on SciRah

Invite

M. Pujana — researcher profile on SciRah

Invite

J. Amézaga — researcher profile on SciRah

Invite

A. Larraioz — researcher profile on SciRah